Loading…
Cardio Diagnostics Holdings, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CDIO.
▼ -99.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.71 | $27.51 | $74.70 | $31.80 | |
| P/S | 2260.5x | 541.0x | 1370.5x | 3150.4x | 10728.0x |
| P/B | 3.7x | 1.2x | 5.0x | 18.2x | 2.4x |
| EPS | -$3.71 | -$9.35 | -$19.80 | -$45.30 | |
| Profit margin | -46460.15% | -43832.49% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CVKDCadrenal Therapeutics, Inc. | $1.54 | — | 1.2x | — | -275.16% | $5.49M |
| LABTLakewood-Amedex Biotherapeutics Inc. | $2.30 | — | 1.2x | — | -402.83% | $5.45M |
| JUNSJupiter Neurosciences Inc | $4.18 | — | — | — | -1888.70% | $5.51M |
| PULMPulmatrix, Inc. | $1.51 |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Company description provided by Yahoo Finance.
| -24028.24% |
| -49087.81% |
| -490630.00% |
| ROE | -100.77% | -93.19% | -87.71% | -283.18% | -108.35% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 3.5x |
| — |
| -98.35% |
| $5.51M |
| PMCBPharmaCyte Biotech, Inc. | $0.52 | — | 0.2x | — | -44.72% | $5.53M |
| NCNANuCana plc | $1.33 | 0.0x | 0.2x | — | -70.26% | $5.54M |